Defying Age: The Intriguing Potential of Interleukin-11 Blockers

A recent study has shed light on the potential of blocking interleukin-11, a protein involved in inflammation, to extend lifespan by over 20%. Conducted on mice, the research highlights the broader implications for aging and disease but emphasizes the need for further human trials and lifestyle changes.

Geelong, Jul 26 (The Conversation) - The media frequently buzzes with tantalizing reports of new drugs that may help us live longer and healthier lives. The latest study focuses on a drug that targets interleukin-11, a protein tied to inflammation, and suggests blocking it can extend life by over 20% in mice.

Conducted in mice, the study involved removing interleukin-11 or treating older mice with a drug to block it, resulting in longer lifespans, reduced cancer risk, and improved health markers. While these findings appear promising, researchers caution the translation of these results to human therapies remains distant.

Chronic inflammation plays a significant role in disease and aging. While direct lifestyle changes are vital, pharmaceutical interventions targeting inflammation are being explored. Despite the compelling findings, scientists emphasize the need for more robust evidence and human trials before adopting any new therapies. Until then, the best strategies for health and longevity remain rooted in lifestyle choices like diet, exercise, and social connections. GRS GRS

(With inputs from agencies.)